
Olympus Announces Launch of Single-Use Hemostasis Clip
Olympus, a global medical technology company committed to making people’s lives healthier, safer and more fulfilling, announced today the launch of a new hemostasis clip to help meet the needs of GI endoscopists. Olympus Corporation of the Americas reports.
The Retentia™ HemoClip provides 360° rotation and an intuitive one-step deployment, offering control over placement with three different sizes to accommodate a variety of closure applications.1 It will launch in the U.S, with plans for further global expansion.
The Retentia™ HemoClip offers the following benefits:
- Arm lengths of 9mm, 12mm, and 16mm to accommodate a variety of closure applications1
- A short tail length which helps with visualization of the target site, potentially facilitating the placement of multiple clips compared to long tail lengths1
- Sheath markings that are designed to aid in insertion and extraction1
- An intuitive handle design which enables the clip to be deployed in a single step1.
Performing hemostasis within the GI tract is a technically demanding procedure and use of hemostatic clips and associated devices may result in patient injury including but not limited to inflammatory reaction, infection, bleeding and perforation.
“The Retentia™ HemoClip is another example of Olympus’ commitment to understanding the needs of clinicians and addressing them, and for this reason among others, we are excited to bring this solution to the market,” said Mike Callaghan, Global VP and General Manager for EndoTherapy, Olympus Corp. of the Americas. “As procedural needs within GI endoscopy continue to evolve, so too must our solutions. Features like ease in deployment and a broad range of size options have become imperative for procedure success, and we’re proud to deliver on these improvements for GI endoscopists.”
The Retentia™ HemoClip is part of a comprehensive Olympus EndoTherapy portfolio that provides physicians with advanced solutions for procedures such as endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD).
EMR and ESD2 are techniques for removing cancerous or other abnormal tissues from the digestive tract. Olympus’ endoscopic portfolio includes devices such as electrosurgical knives, and hemostatic forceps that provide targeted monopolar coagulation. The portfolio also includes technology to help detect and control gastrointestinal bleeding in combination with conventional techniques such as clips.
Hemostasis is an important concern for GI physicians, and the Retentia™ HemoClip reflects Olympus’ continued focus on solving the challenge of bleeding during endoscopic procedures. Olympus’ Red Dichromatic Imaging (RDI™) technology, a feature of the EVIS X1™ endoscopy system, helps improve the visibility of bleeding points within the mucosa and enhances the visibility of deep blood vessels compared to white light.3 RDI™ technology is not intended to replace histopathological sampling as a means of diagnosis. In addition, EndoClot® Polysaccharide Hemostatic Spray (PHS) is a powder hemostat indicated for use, in combination with other conventional techniques like clips, to control bleeds.
Visit the gastroenterology or hemostasis product pages for more information about the entire Olympus GI portfolio.
As a leading medical technology company, Olympus uses medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures with the goal of improving clinical outcomes, reducing overall costs, and enhancing the quality of life for patients. Olympus’ Medical portfolio includes, but is not limited to, endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, system integration solutions, medical services, and a wide range of EndoTherapy devices.
1 Data on File with Yangzhou Fartley Medical Instrument Technology Co., Ltd.
2 ESD is technically demanding, and improper use may result in patient injury, bleeding and/or perforation.
3 Data on file with Olympus (D00489968)
-
Jul 11, 2025, 19:14ISTH 2025 for Cardiac Surgery: LEX-211 (FARES-II) Trial Shows Promising Results
-
Jul 11, 2025, 16:48GPAS 2025: Shaping the Future of Bleeding Disorder Care
-
Jul 10, 2025, 11:23HTRS Thanks CSL Behring for Its Ongoing Commitment to Research Support
-
Jul 9, 2025, 14:11Join Dr. Bethany Samuelson Bannow for a Virtual Event on Hemostasis and Cancer
-
Jul 9, 2025, 13:59Late-Breaking Insights from ISTH 2025: Rurioctocog Alfa Pegol in PUPs with Hemophilia A
-
Jul 12, 2025, 15:221 in 100: Subclavian Steal Syndrome Revealed by LVO Stroke in Case with Persistent Trigeminal Artery
-
Jul 11, 2025, 18:50ICAS Not a Factor: Post-EVT Intensive BP Control within 24 hrs Worsens Outcomes
-
Jul 11, 2025, 17:57Need for Recanalization Strategies Reinforced in P1 and P2: PCA Stroke Poor Outcomes
-
Jul 11, 2025, 15:40Wolfgang Miesbach: How to Better Understand and Explain Gene Therapy of Haemophilia?
-
Jul 11, 2025, 14:53Thrombosis with Thrombocytopenia, Post Vaccination Syndrome
-
Jul 7, 2025, 17:08Detecting Anti-Drug Antibodies to Emicizumab: A French Center’s Remarkable Experience
-
Jul 6, 2025, 21:00From Untouchable to Editable: How 21st-Century Gene Editing Breakthroughs Clash with Systemic Barriers
-
Mar 6, 2025, 17:15Olympus Announces Launch of Single-Use Hemostasis Clip
-
Jul 10, 2025, 18:25Dr. Carol Kasper: Honoring the Legacy
-
Jul 8, 2025, 08:26ASH and HVO Collaborate to Expand Hematology Training in LMICs
-
Jul 6, 2025, 15:02Patients as Experts: EHC Calls for Early Involvement in HTA Systems
-
Jul 6, 2025, 14:56Missed ISTH 2025? Congress Daily Has You Covered
-
Jul 6, 2025, 11:48Japan's Youth Engagement in Hemophilia Care: Where Even the Doctors Get It – HABIT Summit 2025